Marco Ladetto
Associate Professor of Hematology, President of FIL
University of Eastern Piedmont / Azienda Ospedaliera SS Antonio e Biagio · Alessandria, Italy
Italian MCL expert and MRD pioneer. Has advanced molecular monitoring techniques in MCL and led Fondazione Italiana Linfomi MCL studies.
Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.
Blood advances · Jul 24, 2026
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jul 14, 2026
Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology.
Leukemia · Jul 7, 2026
Towards the Definition of a Prognostic Model for Mantle Cell Lymphoma.
Studies in health technology and informatics · May 21, 2026
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.
Lancet (London, England) · May 16, 2026
Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53).
British journal of haematology · May 14, 2026
Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)-MCL0208 clinical trial.
HemaSphere · May 1, 2026
Evolving therapeutic strategies in mantle cell lymphoma: advancements and future directions.
Leukemia · Apr 15, 2026
Clinical impact of immunoglobulin heavy chain repertoire in mantle cell lymphoma: A study from the Fondazione Italiana Linfomi (FIL) Phase III MCL0208 trial.
HemaSphere · Jan 1, 2026
The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial.
Leukemia · Jan 1, 2026
Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.
Leukemia · Jan 1, 2026
Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensus.
Cytotherapy · Nov 1, 2025
Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020.
Haematologica · Oct 30, 2025
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study.
The Lancet. Haematology · Oct 1, 2025
EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma.
HemaSphere · Oct 1, 2025
The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatment.
BMC cancer · Aug 25, 2025
Next-Generation Therapies in Mantle Cell Lymphoma (MCL): The Evolving Landscape in Treatment of Relapse/Refractory After CAR-T Cells.
Cancers · Jul 3, 2025
Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trial.
Blood advances · Apr 22, 2025
Stem cell collection and hematological recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trial.
Scientific reports · Jul 23, 2024
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
Lancet (London, England) · May 25, 2024
Unmet needs in relapsed/refractory mantle cell lymphoma after failure of covalent Bruton's tyrosine kinase inhibitors: An Italian scenario.
Hematological oncology · Jan 1, 2024